Zelenectide pevedotin is under clinical development by Bicycle Therapeutics and currently in Phase III for Kidney Cancer (Renal Cell Cancer). According to GlobalData, Phase III drugs for Kidney Cancer (Renal Cell Cancer) have a 55% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Zelenectide pevedotin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Zelenectide pevedotin overview
BT-8009 is under development for the treatment of solid tumors like metastatic urothelial (transitional cell) carcinoma, renal cancer, ureter cancer, urethral cancer, non-small cell lung cancer, esophageal cancer, bladder cancer, urothelial carcinoma, pancreatic cancer, gastric cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, head and neck cancer and triple negative breast cancer. The drug candidate is a bicyclic peptide conjugate being developed based on bicyclic peptide technology. It acts by targeting nectin-4 linked to the cytotoxin monomethyl auristatin E (MMAE) by a molecular spacer and cleavable linker. It is administered through intravenous route.
Bicycle Therapeutics overview
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of molecules for the treatment of cancers and other debilitating diseases. The company’s Bicycle Toxin Conjugates (BTC) pipeline includes BT1718, BT5528, and BT8009 for the indication of metastatic urothelial cancer and others. Its Immuno-oncology pipeline products include BT7480, BT7401 and BT7455. Bicycle Therapeutics collaborates with other biotechnology companies for the development of bicyclic peptide inhibitors for the treatment of ophthalmic diseases such as diabetic macular edema, renal elimination, versatility for multimerization and conjugation. The company operates in the UK and the US. Bicycle Therapeutics is headquartered in Cambridge, Cambridgeshire, the UK.
For a complete picture of Zelenectide pevedotin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
